Growth-hormone pathway peptides, explained

People usually arrive here from one of three questions: they have read that growth-hormone levels decline with age and want to understand what that means; they have seen names like sermorelin or ipamorelin and want to know how they differ from growth hormone itself; or a clinician has mentioned a "secretagogue" and they want a plain-language explanation before a conversation.

The short version: these peptides are studied for their effect on the body's own signalling rather than as replacement hormone. That distinction matters for how the research is designed and for what a provider can and cannot responsibly say.

Sermorelin has the longest history: it was FDA-approved for a paediatric diagnostic and treatment use and later withdrawn from the market for commercial reasons, so there is a body of human pharmacology data, but not approval for the questions adults typically ask. CJC-1295 and ipamorelin have human pharmacokinetic and hormone-response studies but no approval for any use. GHRP-2 and GHRP-6 were studied mainly as research tools and diagnostics.

What none of these have is an approved indication for healthy adults, and the long-term safety data in that population is limited. A responsible provider will tell you that before anything else.

You leave Vitrex for Doctor G Medical's secure portal, complete a confidential intake (about 10 minutes, free), and a licensed provider reviews it. If growth-hormone-pathway questions are relevant to your history, the provider may discuss options; if not — or if your state restricts them — they say so. Nothing is charged before a written quote.